Immune response regulation by transduced mesenchymal stem cells with *decorin* gene on bleomycin-induced lung injury, fibrosis, and inflammation

Wei Xu\(^a\#\), Chang Kun Li\(^b\#\), Li Sha Yang\(^c\), Entezar Mehrabi Nasab\(^{d,e}\), Seyyed Shamsadin Athari\(^f\), Wen Dong Gu\(^*\)

\(^a\)Department of Infectious Diseases, The First People’s Hospital of Shuangliu District Chengdu, Chengdu Sichuan, China
\(^b\)Department of Anesthesiology, Baodi Clinical College, Tianjin Medical University, Tianjin, China
\(^c\)Department of Respiratory and Critical Care Medicine, The First People’s Hospital of Shuangliu District Chengdu, Chengdu Sichuan, China
\(^d\)Department of Cardiology, School of Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
\(^e\)Department of Cardiology, School of Medicine, Valiasr Hospital, Zanjan University of Medical Sciences, Zanjan, Iran
\(^f\)Department of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
\(^g\)Department of Pneumology, Suzhou Wuzhong People’s Hospital, Suzhou Jiangsu, China

\(^\#\)Wei Xu and Changkun Li are first co-authors with equal contributions to this work.

Received 5 April 2023; Accepted 26 April 2024
Available online 1 July 2024

**Abstract**

**Background:** Pulmonary fibrosis is a pathological hallmark of lung injury. It is an aggressive disease that replaces normal lung parenchyma by fibrotic tissue. The transforming growth factor-beta-mothers against decapentaplegic homolog 3 (TGF-β1–Smad3) signaling pathway plays a key role in regulating lung fibrosis. *Decorin* (DCN), a small leucine-rich proteoglycan, has a modulatory effect on the immune system by reversibly binding with TGF-β and reducing its bioavailability. Mesenchymal stem cell (MSC) therapy is a new strategy that has an immune-modulatory capacity.

**Objective:** The aim of this study was to introduce a new therapeutic approach to harness remodeling in injured lung.

**Material and Methods:** Bone marrow MSCs were isolated and transduced by *decorin* gene. Lung injury was induced by bleomycin and mice were treated with MSCs, MSCs–*decorin*, and *decorin*. Then, oxidative stress biomarkers, remodeling biomarkers, bronchoalveolar lavage cells, and histopathology study were conducted.

**Results:** Reduced catalase and superoxide dismutase increased due to treatments. Elevated malondialdehyde, hydroxyproline, TGF-β levels, and polymorphonuclear cells count decreased
Introduction

Lung injury is caused by a wide range of harmful components and/or pathogens. In its chronic form, it can lead to the remodeling and fibrosis of lung tissue. Pulmonary fibrosis is a pathological hallmark of heterogeneous disorders in which excessive collagen accumulation results from a variety of insults to the lung. The pathogenetic mechanisms of lung fibrosis are hindered. In response to injury and oxidants, fibroblasts become active and produce collagen. In patients with pulmonary fibrosis, an imbalance between oxidant and antioxidant defense mechanisms is created in the microenvironment of target lung. Lung fibrosis is one of the aggressive diseases and after the onset of symptoms, has a median survival of 3-5 years. The normal lung parenchyma is replaced by fibrotic tissue accompanied by fibroblast proliferation, inflammation, and excessive deposition of collagen. The scar tissue leads to irreversible decrease in the diffusion capacity of oxygen in the lungs. The cellular and molecular mechanisms involved in the pathogenesis of lung fibrosis are largely unclear, and presently no medications are available to prevent or reverse lung fibrogenesis. The transforming growth factor (TGF)-β1–mothers against decapentaplegic homolog 3 (Smad3) signaling pathway plays a key role in regulating lung fibrosis. TGF-β1 induces lung fibroblast differentiation into myofibroblasts, and deficiency of Smad3 attenuates bleomycin-induced lung fibrosis. Tranilast, a macrophage inhibitor, reduces the severity of bleomycin-induced lung fibrosis. Fibroblasts, myofibroblasts, type II alveolar epithelial cells, macrophages, and eosinophils are the key cells that produce TGF-β1 in fibrotic lungs. Novel therapeutic strategies through advances in gene-cell therapy are expected to become available soon. It is hoped that what was learned regarding the pathogenesis of fibrosis would soon be used in designing new ways to treat lung fibrosis.

*Decorin* as an internal bio-molecule is small leucine-rich proteoglycan and has modulatory effect on the immune system. It is able to control tissue remodeling and in continuous, reduces fibrosis. *Decorin* is an extracellular matrix proteoglycan and is involved in the formation and stability of collagen fibers. It affects airway parenchymal interdependence, proliferation of airway smooth muscle cells, and bioavailability of TGF-β. *Decorin* reversibly binds with the TGF-8 core protein and reduces its bioavailability.

Mesenchymal stem cells regulate other cell functions, translocate to inflamed tissues, and help to repair injured tissues. MSCs promote repair and ameliorate injured tissues, such as lungs. Furthermore, MSCs have low immunogenicity and modulate proliferation of regulatory T cells (Tregs) and interleukin (IL)-10, TGF-β1 secretions. MSCs therapy is a new strategy with immune-modulatory capacity. MSCs through an immune system modulatory effect may control inflammation. The aim of the current study was to introduce a new therapeutic approach with a long-term effect on lung fibrosis. In this study, immune-modulatory effect, harnessing of remodeling factors, and protective effect of transduced MSCs with the expression *decorin* gene in injured lung was evaluated.

Materials and Methods

Isolation and transduction of MSCs

Bone marrow MSCs were isolated from the tibia and femur of mouse according to a previous study and transduced by *decorin* gene. The cells were analyzed after culture and passage. The expression vector containing a fully sequenced open reading frame was prepared and the expression vector of *decorin* gene was transduced to MSCs. The pAAV-CMV-DCN plasmid was used as an expression vector to contain the expressible mouse *decorin* gene. To express *decorin* gene, total RNA was isolated from transduced MSCs. After synthesizing complementary DNA (cDNA), real-time polymerase chain reaction was performed using specific primers for *decorin* gene.

Animals

Six 8-week-old male BALB/c mice (mean body weight: 21±2 g) were acclimatized for adaptation under standard conditions (24±2° C temperature, 65±15% humidity, and 12-h light/dark cycle) to pathogen-free environment in an animal room for 1 week prior to examination.

Animal modeling and treatment schedule

A total of 35 mice were allocated to five groups (n = 7). In four groups, lung injury was induced by bleomycin according to the method described in the past. Animal groups included the sham group (group S), bleomycin-induced lung injury group (group B), MSCs treatment group (group M), MSCs-decorin treatment group (group M-D), and decorin treatment group (group D). Lung injury and fibrosis were induced by a single intratracheal instillation of bleomycin (5 mg/kg in 0.3-mL saline) in all four groups, and the sham group received an equal volume of saline. Beginning on day 14 after administration of bleomycin, mice in groups M, D, and M-D received MSCs, decorin, and transduced MSCs with *decorin* gene, respectively. On day 28, lung tissue, bronchoalveolar lavage (BAL) fluid, and blood samples were collected and animals were euthanized.
**Oxidative stress biomarkers**

For oxidative stress indicators, malondialdehyde (MDA) level in plasma, superoxide dismutase (SOD) pulmonary levels, and catalase (CAT) were measured using lung tissues.\(^\text{13}\) Level of SOD was calculated from the absorption features of lung tissue samples, and the results were expressed as (IU/mg protein). Level of CAT was evaluated by a colorimetric method, which was performed by incubating lung tissue with H\(_2\)O\(_2\). The absorption of CAT was studied and the result was expressed as (μmol H\(_2\)O\(_2\)/min/mg protein).

**Fibrotic (remodeling) biomarkers**

In lung tissue, level of hydroxyproline (HP) was an important index for deposition of collagen fibers, which was measured by a colorimetric modified method.\(^\text{13}\) Lung tissue homogenates were hydrolyzed in HCL, and NaOH was added to hydrolyzed samples for neutralization. Chloramine T reagent was also added, and for inactivation, perchloric acid was added. Afterwards, Ehrlich's solution was also added until the appearance of a reddish color. The results were expressed as milligrams of HP per gram of lung tissue (mg/g).

In addition, TGF-β, one of the other remodeling factors, was measured in supernatants of lung tissue homogenate as described previously.\(^\text{13}\)

**BAL cells**

Following the sampling of BAL, cytospin slides were prepared from BAL cells and stained subsequently. The presence of polymorphonuclear cells (PMNC) was evaluated and reported as a percentage of all white blood cells (WBC).\(^\text{9–13,29,31}\)

**Histopathology**

Parts of lung tissues were maintained in formalin solution until fixation; the sections were prepared and stained with hematoxylin and eosin (H&E) stain. Later, inflammation, remodeling, and fibrosis were evaluated in histopathological sections and determined in 10 randomly selected microscopy fields of sections at magnification ×400. Histologic grading of lesions was conducted with the Szapiel method for extent of inflammation in lung parenchyma base, and the microscopic interstitial inflammation and degree of fibrosis were graded on a scale of 1-4 (absent, light, moderate, and strong). Collagen deposition was measured by Masson's trichrome staining. Percentage of fibrosis in the lung was determined by counting the number of pixels within the areas of stained collagen in digital images. Interstitial inflammation and fibrosis microscopic degrees were graded on a scale of 1-4 (absent, light, moderate, and strong). Photomicrographs were taken using microscope equipped with a digital camera.

**Statistical analysis**

All experiments were repeated thrice and the results were expressed as mean ± standard deviation (SD) of the indicated number of independent experiments. Correlation was analyzed using Pearson's method. The paired t-test was used to analyze differences between groups. In multiple comparisons, one-way ANOVA followed by Tukey's honestly significant difference (HSD) tests were used. P < 0.05 was considered as statistically significant. SPSS (ver. 22) was used for analysis and performed using GraphPad Prism (version 5.0).

**Result**

**Oxidative stress biomarkers**

Catalase decreased significantly in group B (P < 0.05), compare to group S (38±4 and 92±5 μmol H\(_2\)O\(_2\)/min/mg protein, respectively). Treatments increased significantly the levels of CAT (P < 0.05), compared to group B (Figure 1). The increase was significant in group M-D (44±3 μmol H\(_2\)O\(_2\)/min/mg protein), compared to other treated groups (M and D groups).

Superoxide dismutase decreased significantly in group B (P < 0.05), compared to group S (31±5 and 96±4 IU/mg protein, respectively). Treatments could increase significantly the levels of SOD (P < 0.05), compared to group B (Figure 1). The increase was significant in group M-D.

![Figure 1](image-url) Oxidative stress biomarkers. Levels of CAT, SOD, and MDA were evaluated in all groups, and it was observed that treatments had significant effect on these biomarkers.
The PMNCs were observed to increase significantly in group B ($P < 0.05$), compared to group S ($87\pm5\%$ and $8\pm2\%$, respectively); however, treatments could control PMNC of BAL cells (Figure 3). This control was significant in group M-D ($P < 0.05$), compared to groups M and D ($26\pm12\%$, $63\pm7\%$, and $59\pm4\%$, respectively).

**Histopathology**

In the histopathology evaluation of lung tissues, it was observed that inflammation and fibrosis were increased significantly ($P < 0.05$) in group B ($3.7\pm0.2$ and $3.5\pm0.4$, respectively), compared to group S ($0.5\pm0.1$ and $0.5\pm0.0$, respectively); however, treatments could significantly control inflammation and fibrosis ($P < 0.05$), compared to group B (Figure 4). The controlling was significant in group M-D ($1.1\pm0.2$ and $0.9\pm0.3$, respectively), compare to other treated groups (M and D groups).

**Discussion**

Bleomycin as antitumor factor and antibiotic was isolated from the fungus *Streptomyces verticillus*, which exerts antitumor activity by inducing tumor cell death and tumor angiogenesis inhibition. It is used as an antitumor therapy for different tumors, such as cervical cancer, Kaposi’s sarcoma, and squamous cell carcinomas of the head and neck. Bleomycin has a major limitation, as it usually causes pulmonary toxicity. Several distinct pulmonary syndromes are linked to bleomycin usage, including eosinophilic hypersensitivity, bronchiolitis obliterans with organizing pneumonia, and, most commonly, interstitial pneumonitis that may progress to fibrosis. The bleomycin-induced lung injury mechanism is not clear and potentially involves oxidative damage, elaboration of inflammatory cytokines, genetic susceptibility, and relative deficiency of the deactivating enzyme bleomycin hydrolase.

---

(36±4 IU/mg protein), compared to other treated groups (M and D groups).

The levels of MDA were increased significantly in group B, compared to group S ($3.1\pm0.2$ and $1.3\pm0.1$ nmol/mg protein, respectively; $P < 0.05$). Treatments decreased significantly the levels of MDA, compared to group B ($P < 0.05$) (Figure 1). The most significant decrease was observed in group M-D ($1.7\pm0.2$ nmol/mg protein), compared to other treated groups (M and D groups).

**Fibrotic (remodeling) biomarkers**

Hydroxyproline elevated significantly in group B ($P < 0.05$), compare to group S ($6.1\pm0.4$ and $1.6\pm0.2$ mg/g, respectively); treatments could significantly control the level of HP ($P < 0.05$), compare to group B (Figure 2). The controlling was significant in group M-D ($2.7\pm0.2$ mg/g), compare to other treated groups (M and D groups).

TGF-β increased significantly in group B ($P < 0.05$), compare to group S ($411\pm16$ and $76\pm11$ pg/mL, respectively); treatments could significantly decrease the levels of TGF-β ($P < 0.05$), compare to group B (Figure 2). The decrease was significant in group M-D ($92\pm8$ pg/mL), compared to other treated groups (M and D groups).

**BAL cells**

The PMNCs were observed to increase significantly in group B ($P < 0.05$), compare to group S ($87\pm5\%$ and $8\pm2\%$, respectively); however, treatments could control PMNC of BAL cells (Figure 3). This control was significant in group M-D ($P < 0.05$), compared to groups M and D ($26\pm12\%$, $63\pm7\%$, and $59\pm4\%$, respectively).

**Histopathology**

In the histopathology evaluation of lung tissues, it was observed that inflammation and fibrosis were increased significantly ($P < 0.05$) in group B ($3.7\pm0.2$ and $3.5\pm0.4$, respectively), compared to group S ($0.5\pm0.1$ and $0.5\pm0.0$, respectively); however, treatments could significantly control inflammation and fibrosis ($P < 0.05$), compared to group B (Figure 4). The controlling was significant in group M-D ($1.1\pm0.2$ and $0.9\pm0.3$, respectively), compare to other treated groups (M and D groups).

---

**Discussion**

Bleomycin as antitumor factor and antibiotic was isolated from the fungus *Streptomyces verticillus*, which exerts antitumor activity by inducing tumor cell death and tumor angiogenesis inhibition. It is used as an antitumor therapy for different tumors, such as cervical cancer, Kaposi’s sarcoma, and squamous cell carcinomas of the head and neck. Bleomycin has a major limitation, as it usually causes pulmonary toxicity. Several distinct pulmonary syndromes are linked to bleomycin usage, including eosinophilic hypersensitivity, bronchiolitis obliterans with organizing pneumonia, and, most commonly, interstitial pneumonitis that may progress to fibrosis. The bleomycin-induced lung injury mechanism is not clear and potentially involves oxidative damage, elaboration of inflammatory cytokines, genetic susceptibility, and relative deficiency of the deactivating enzyme bleomycin hydrolase.
In animal models of bleomycin toxicity, dust cells (alveolar macrophages) release cytokines, such as IL-1, macrophage inflammatory proteins (MIP)-1, platelet-derived growth factor (PDGF), and TGF-β, which can lead to fibrosis. The activation of epithelial cells and damage causes the release of cytokines and growth factors, which stimulate the proliferation of myofibroblasts and the secretion of pathologic extracellular matrix, finally leading to fibrosis. Tumor necrosis factor (TNF)-α, TGF-β, and PDGF receptor-α (PDGFR-α) stimulate the transformation, proliferation, and accumulation of fibroblasts, leading to the deposition of extracellular matrix. This progressive accumulation of collagen matrix results in the distortion and destruction of alveolar structures, leading to a loss of lung function.

Bleomycin may also up-regulate collagen synthesis by modulating fibroblast proliferation via TGF-β response, which results in irreversible pulmonary fibrosis. It was reported that the treatment of bleomycin-induced lung injury mouse model with montelukast reduced fibrotic area and HP content in fibrotic lungs. Montelukast exhibits its effects by inhibition of the IL-6, IL-10, IL-13, and TGF-β1 overexpression. In a study, the effect of all-trans retinoic acid on bleomycin-induced lung fibrogenesis and the role of TGF-β1-Smad3 signaling pathway were investigated. It was observed that bleomycin increased thickness of the alveolar wall, infiltration of inflammatory cells, and formation of collagen fibers. The all-transretinoic acid ameliorated bleomycin-induced lung fibrosis, and these anti-fibrotic effects could be mediated by inhibition of epithelial-mesenchymal transition (EMT) through the down-regulation of TGF-β1-Smad3 signaling pathway. In addition, it ameliorates bleomycin-induced EMT by inhibiting α-SMA-expressing myofibroblasts and expression of collagen and enhancing expression of E-cadherin in fibroblasts. In lung fibrosis, fibroblasts differentiate into myofibroblasts that exhibit enhanced fibrotic and contractile activities. Lung fibrosis is regulated by TGF-β1-Smad3 signaling pathway activated by contraction of myofibroblast, and this pathway promotes fibrotic transformation of the lung through EMT activation. Bleomycin increases PMNC in BAL of injured lungs. In our study, the cells were increased in BAL of nontreated bleomycin-induced lungs injury controlled by cell therapy, decorin therapy, and especially in treated group, with transduced MSCs with decorin gene.

The oxidative lung injury and pulmonary fibrosis can be induced via bleomycin administration, and the related pathophysiology typically consists of two overlapping phases. The early inflammatory phase (leucocyte infiltration) leads to alveolar epithelial cells injury and the subsequent fibroproliferative phase with matrix remodeling and fibrosis. Pulmonary fibrosis is commonly mediated by TGF-β, which enhances collagen gene expression and protein deposition. In addition, TGF-β mediates the depletion of alveolar glutathione stores and promotes acute lung injury. CAT and SOD are the main biomarkers in oxidative stress pathway, which were decreased in the bleomycin-induced lung and in this study, treatments could increase CAT and SOD levels. The increasing CAT and SOD levels were significant in group M-D, compared to other treated groups, and it was demonstrated that transduced MSCs with decorin gene had a strong effect. In this study, we found that MDA levels were increased in the bleomycin-induced group. However, treatments were effective in controlling MDA levels. Notably, group M-D showed a significant decrease in MDA levels, compared to other two treated groups (MSCs and decorin groups).

Collagen fibers as connective tissue elements are clearly responsible for fibrosis in bleomycin-induced lungs, and collagen type I gene expression is preceded by collagen type VI gene expression. Fibroblast and myofibroblast cells synthesize extracellular matrix proteins, which are the core of fibrotic transformation in the lung. Decorin deficiency enhances collagen deposition and airway remodeling in the lung. Decorin modulates essential biological processes and biofactors, including collagen fibrillogenesis, and affects smooth muscle contractility, immune system responsiveness, and cell migration. In fibrotic diseases, TGF-8 initiates remodeling and fibrosis, which is inhibited by decorin. Decorin can down-regulate TGF-β and inhibit elevated expression of TGF-β-driven profibrogenic genes, formation of myofibroblasts, fibrosis, tenasin, fibronectin, and collagen types I and IV. Furthermore, decorin regulates both inflammation and fibrillogenesis processes. As a natural product has no immune response and can be used as a therapeutic agent to control lung remodeling. In addition, decorin gene therapy inhibits TGF-β-driven fibrosis. In bleomycin-induced lung, both HP and TGF-β were elevated significantly; however, treatments controlled HP and TGF-β levels. The controlling was more notable in group M-D, compared to other treated groups (M and D groups).

Cell administration for immunomodulation is a recent therapeutic method for immune system-related diseases. Therefore, immune response modulation by cell therapy could be used as a treatment of inflammatory diseases. MSCs immunomodulation is a new therapeutic approach for a variety of immune-response diseases and is able to alleviate airway inflammation. In the presence of inflammation, MSCs suppress immune response and T cell proliferation by secreting prostaglandin E2 (PGE2) and indoleamine 2-3-dioxigenase (IDO). The immunomodulation is achieved through the secretion of TGF-β and PGE2, which decreases T cell proliferation and increases the proportion of T regulatory cells. Vector direct injection can stimulate immune response against vector that removes them prior to entering target cells, while MSCs are almost non-immunogenic. Therefore, using transfected MSCs with target expression of decorin gene is used to treat uncontrolled lung injury. Systemic administration of MSCs could suppress remodeling of airway. MSCs have a high degree of plasticity and are capable of differentiating into bronchial, alveolar, and interstitial cell types in the lung. They play a significant role in modulating local inflammation and repairing injured lung tissue. In the histopathology evolution of lung tissues in the current study, it was observed that inflammation and fibrosis as main problems in lung injury were increased by bleomycin; however, treatments controlled inflammation as well as fibrosis. The group that received MSCs containing decorin gene exhibited dominant control, compared to the group that received MSCs without decorin gene and the group that received only decorin gene.

Mesenchymal stem cells are immunomodulatory cells, and in asthmatic lungs could up-regulate IL-10. In
addition, MSCs promote immunosuppressive effect, and the intranasal administration of MSCs enhances immuno-suppressive cytokine IL-10 production by lung interstitial macrophages. Inflammation has a notable role in lung injury, but MSCs have a protective effect in lung injury. It may be enhanced if combined with the protective effect of IL-35. It was reported in a study that transduced MSCs with IL-35 expression gene controlled immunopathology. Mechanism of inflammation in asthma and immunomodulatory potential of MSCs had synergism with IL-35 effect.

In the current study, we transfected decorin gene into MSCs to control bleomycin-induced lung injury. Our results showed that transduced MSCs with decorin gene effectively controlled remodeling, inflammation, and fibrosis in the lung, thus preventing lung injury. Our study had few limitations. First, we could not check the effect of transduced MSCs with decorin gene in chronic lung injury. In addition, we could not evaluate other related biofactors and immune system-related responses and molecules.

Ethics Approval and Consent to Participate

The current study was approved by the Ethics Committee of Animal House of ix.med.vet.dep, 2023 (No. IX.MED.VET. DEP.REC.2023.0100099.5). All methods were performed in accordance with the relevant guidelines and regulations.

Conflict of Interest

There was no conflict of interest to declare.

Author contributions

Wei Xu, Chang Kun Li, Li Sha Yang, Entezar Mehrabi Nasab, Seyyed Shamsadin Athari, and Wen Dong Gu participated in planning of the project, animal study, laboratory testing, analysis of data, and writing of the manuscript.

Funding

The study was supported by Health Commission of Chengdu (evaluation of cardiovascular function in gestational hypertension pregnant women by continuous Doppler hemodynamics monitoring, Wei Xu) with NO: 2021374.

References